Cita APA

Palafox Sánchez, M., Monserrat Vicente, L., Bellet Ezquerra, M., Villacampa, G., González Pérez, A., Oliveira, M., . . . Serra Elizalde, V. (2022). High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER⁺ breast cancer.

Citación estilo Chicago

Palafox Sánchez, Marta, et al. High P16 Expression and Heterozygous RB1 Loss Are Biomarkers for CDK4/6 Inhibitor Resistance in ER⁺ Breast Cancer. 2022.

Cita MLA

Palafox Sánchez, Marta, et al. High P16 Expression and Heterozygous RB1 Loss Are Biomarkers for CDK4/6 Inhibitor Resistance in ER⁺ Breast Cancer. 2022.